Tumor-suppressive MicroRNA-452 Inhibits Migration and Invasion of Breast Cancer Cells by Directly Targeting RAB11A

Overview

Journal Oncol Lett

Specialty Oncology

Date 2017 Aug 8

PMID 28781694

Citations 15

Authors

Wanjun Li

Guoyin Li

Zhigang Fan

Tao Liu

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most common type of malignant tumor in females, and metastasis is the most common cause of breast cancer-associated mortality. Previous studies have identified that abnormal expression of microRNAs is commonly observed in human cancer and may be crucial for cancer metastasis. In the present study, microRNA-452 (miR-452) was investigated for its ability to act as a tumor suppressor in breast cancer. miR-452 expression was quantified in breast cancer tissue samples and cell lines with reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Transwell migration and invasion assays were used to investigate the effect of miR-452 on the migration and invasion capabilities of breast cancer cells. Potential target genes of miR-452 were identified with miRanda and TargetScan. A luciferase reporter assay was performed to validate RAB11A as a putative target of miR-452, and was corroborated by RT-qPCR and western blot analyses. Finally, small interfering RNA (siRNA) was used to knockdown RAB11A expression and confirm whether miR-452 inhibited breast cancer cell migration and invasion via the negative regulation of RAB11A. The results revealed that miR-452 was downregulated in breast cancer tissues and cell lines, and that its downregulation may be associated with breast cancer metastasis, as miR-452 expression inhibited the migration and invasion capacities of breast cancer cells. RT-qPCR and western blot analyses indicated that miR-452 negatively regulated the expression of RAB11A mRNA and protein. The luciferase reporter assay revealed that miR-452 specifically bound to the 3'-untranslated region of RAB11A. Furthermore, inhibition of RAB11A with siRNA inhibited breast cancer cell migration and invasion. In conclusion, the present study has demonstrated that miR-452 may act as a tumor suppressor gene via inhibition of cell migration and invasion by targeting RAB11A in breast cancer.

Citing Articles

Membrane trafficking alterations in breast cancer progression.

Ferreira A, Castanheira P, Escrevente C, Barral D, Barona T Front Cell Dev Biol. 2024; 12:1350097.

PMID: 38533085 PMC: 10963426. DOI: 10.3389/fcell.2024.1350097.

Genetic variations in tumor-suppressor miRNA-encoding genes and their target genes: focus on breast cancer development and possible therapeutic strategies.

Chhichholiya Y, Singh H, Singh S, Munshi A Clin Transl Oncol. 2023; 26(1):1-15.

PMID: 37093457 DOI: 10.1007/s12094-023-03176-8.

MicroRNA-452: a double-edged sword in multiple human cancers.

Dermani F, Datta I, Khoei S Clin Transl Oncol. 2023; 25(5):1189-1206.

PMID: 36622551 DOI: 10.1007/s12094-022-03041-0.

Extracellular vesicles derived from Wharton's Jelly mesenchymal stem cells inhibit the tumor environment via the miR-125b/HIF1α signaling pathway.

Chang Y, Vuong C, Ngo N, Yamashita T, Ye X, Futamura Y Sci Rep. 2022; 12(1):13550.

PMID: 35941273 PMC: 9359975. DOI: 10.1038/s41598-022-17767-y.

Variation in the co-expression profile highlights a loss of miRNA-mRNA regulation in multiple cancer types.

Pepe G, Parca L, Viviani L, Ausiello G, Helmer-Citterich M Noncoding RNA Res. 2022; 7(2):98-105.

PMID: 35387279 PMC: 8958468. DOI: 10.1016/j.ncrna.2022.03.003.

References

Bockhorn J, Prat A, Chang Y, Liu X, Huang S, Shang M . Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models. Cancer Res. 2014; 74(24):7406-17. PMC: 4310213. DOI: 10.1158/0008-5472.CAN-14-1188. View

Sun E, Zhou Q, Liu K, Wei W, Wang C, Liu X . Screening miRNAs related to different subtypes of breast cancer with miRNAs microarray. Eur Rev Med Pharmacol Sci. 2014; 18(19):2783-8. View

Teng G, Papavasiliou F . Shhh! Silencing by microRNA-155. Philos Trans R Soc Lond B Biol Sci. 2008; 364(1517):631-7. PMC: 2660923. DOI: 10.1098/rstb.2008.0209. View

Gromak N . Intronic microRNAs: a crossroad in gene regulation. Biochem Soc Trans. 2012; 40(4):759-61. DOI: 10.1042/BST20120023. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

Wang B, Yang Z, Wang H, Cao Z, Zhao Y, Gong C . MicroRNA-320a inhibits proliferation and invasion of breast cancer cells by targeting RAB11A. Am J Cancer Res. 2015; 5(9):2719-29. PMC: 4633901. View

Sharma S, Kelly T, Jones P . Epigenetics in cancer. Carcinogenesis. 2009; 31(1):27-36. PMC: 2802667. DOI: 10.1093/carcin/bgp220. View

Caswell P, Chan M, Lindsay A, McCaffrey M, Boettiger D, Norman J . Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. J Cell Biol. 2008; 183(1):143-55. PMC: 2557049. DOI: 10.1083/jcb.200804140. View

10.

Liu L, Chen K, Wu J, Shi L, Hu B, Cheng S . Downregulation of miR-452 promotes stem-like traits and tumorigenicity of gliomas. Clin Cancer Res. 2013; 19(13):3429-38. PMC: 3725315. DOI: 10.1158/1078-0432.CCR-12-3794. View

11.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

12.

Wu D, Pan H, Zhou Y, Zhang Z, Qu P, Zhou J . Upregulation of microRNA-204 inhibits cell proliferation, migration and invasion in human renal cell carcinoma cells by downregulating SOX4. Mol Med Rep. 2015; 12(5):7059-64. DOI: 10.3892/mmr.2015.4259. View

13.

van Schooneveld E, Wildiers H, Vergote I, Vermeulen P, Dirix L, Van Laere S . Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res. 2015; 17:21. PMC: 4332424. DOI: 10.1186/s13058-015-0526-y. View

14.

Wei C, Luo Q, Sun X, Li D, Song H, Li X . MicroRNA-497 induces cell apoptosis by negatively regulating Bcl-2 protein expression at the posttranscriptional level in human breast cancer. Int J Clin Exp Pathol. 2015; 8(7):7729-39. PMC: 4555666. View

15.

Hong W, Dong E . The past, present and future of breast cancer research in China. Cancer Lett. 2014; 351(1):1-5. DOI: 10.1016/j.canlet.2014.04.007. View

16.

Wang Z, Ouyang G . Periostin: a bridge between cancer stem cells and their metastatic niche. Cell Stem Cell. 2012; 10(2):111-2. DOI: 10.1016/j.stem.2012.01.002. View

17.

Bhuin T, Roy J . Rab11 in disease progression. Int J Mol Cell Med. 2015; 4(1):1-8. PMC: 4359700. View

18.

Takahashi R, Miyazaki H, Ochiya T . The Roles of MicroRNAs in Breast Cancer. Cancers (Basel). 2015; 7(2):598-616. PMC: 4491673. DOI: 10.3390/cancers7020598. View

19.

Wan L, Pantel K, Kang Y . Tumor metastasis: moving new biological insights into the clinic. Nat Med. 2013; 19(11):1450-64. DOI: 10.1038/nm.3391. View

20.

Gamucci T, DOttavio A, Magnolfi E, Barduagni M, Vaccaro A, Sperduti I . Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer. Br J Cancer. 2007; 97(8):1040-5. PMC: 2360453. DOI: 10.1038/sj.bjc.6603982. View